Kirin

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area

Retrieved on: 
Martedì, Dicembre 1, 2020
Kyowa Hakko Kirin, Kirin, Rare disease

Under the terms of the licensing and distribution agreement, Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR in China.

Key Points: 
  • Under the terms of the licensing and distribution agreement, Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR in China.
  • It is a rare disease with about 30,000 diagnosed patients in the world and accounts for approximately 45% of primary cutaneous lymphomas1.
  • Dr. Tan Boon Heon, Kyowa Kirins President in the Asia Pacific, commented: Kyowa Kirin is committed to delivering life-changing value to people living with severe diseases.
  • VALCHLOR joins a growing portfolio of innovative products that we are introducing in the rare disease, nephrology and hemato-oncology space in Asia.

Kyowa Hakko Bio Establishes New Facility in Thailand to Supply Human Milk Oligosaccharides Worldwide

Retrieved on: 
Mercoledì, Novembre 4, 2020
Companies, Branches of biology, Kyowa Hakko Kirin, Kirin Holdings, Kirin Company, Economy of Japan, Kirin, Human milk oligosaccharide

TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.

Key Points: 
  • TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.
  • Kyowa Hakko Bio decided on the move with expectations of a future increase in global demand for HMOs.
  • The new facility is to be established at Kyowa Hakko Bio's subsidiary Thai Kyowa Biotechnologies Co., Ltd. (Thai Kyowa) in Rayong Province, Thailand.
  • Kyowa Hakko Bio will be able to secure a competitive advantage through its strain development and manufacturing process development capabilities.

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

Retrieved on: 
Giovedì, Ottobre 22, 2020
RTT, Kirin, Hyperphosphatemia, Paracellular transport, Biology, Life sciences

In Japan, Kyowa Kirin has conducted three Phase 2 trials of tenapanor as KHK7791.

Key Points: 
  • In Japan, Kyowa Kirin has conducted three Phase 2 trials of tenapanor as KHK7791.
  • Recent advances in our mechanistic understanding of phosphate absorption have led to a whole new way of thinking about how to manage hyperphosphatemia.
  • With its novel mechanism of action targeting paracellular phosphate transport and comprehensive clinical data continuing to support its efficacy and safety, I believe tenapanor, if approved, has the potential to truly transform the management of hyperphosphatemia."
  • In 2017, Ardelyx and Kyowa Kirin entered into a license agreement that provides Kyowa Kirin exclusive rights to develop and commercialize tenapanor in Japan for the treatment of cardiorenal diseases.

Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma

Retrieved on: 
Venerdì, Ottobre 2, 2020
Kyowa Hakko Kirin, Kirin, Companies, Pharmacology

In April 2020,MEI and Kyowa Kirin entered aglobal license, development, and commercialization agreement to further develop and commercialize zandelisib.

Key Points: 
  • In April 2020,MEI and Kyowa Kirin entered aglobal license, development, and commercialization agreement to further develop and commercialize zandelisib.
  • MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales.
  • Ongoing zandelisib studies also include a Japanese Phase 2 pivotal study in patients withiNHL without small lymphocytic lymphoma, LPL and WM being conducted by Kyowa Kirin.
  • We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin

Retrieved on: 
Mercoledì, Agosto 5, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cars, Chemical compounds, Transport, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Avianca, Kyowa Hakko Kirin, Tivozanib, Kirin, Chevrolet Aveo, Tivozanib (FOTIVDA, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).
  • This milestone marks an important step forward for AVEOs non-oncology pipeline, said Michael Bailey, president and chief executive officer of AVEO.
  • We believe tivozanibs potential in non-oncology indications is significant, and we look forward to seeing Kyowa Kirin move this formulation into the clinic.
  • Under the terms of AVEOs agreement with Kyowa Kirin, in addition to the previously-paid upfront payment of $25 million to AVEO and waiver of AVEOs obligation to make an $18 million milestone payment upon AVEO gaining U.S. marketing approval of tivozanib for renal cell carcinoma, and now the IND development milestone, Kyowa Kirin has also agreed to pay AVEO up to an additional $388 million in potential milestone payments upon the successful achievement of certain development, regulatory, and commercial objectives in non-oncology indications of tivozanib.

4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board

Retrieved on: 
Lunedì, Luglio 13, 2020
American football in Japan, Keio University, Minato, Tokyo, Kirin

Brings extensive experience in gut microbiota, a core area of interest for 4BIO

Key Points: 
  • Brings extensive experience in gut microbiota, a core area of interest for 4BIO
    LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Kenya Honda to its Scientific Advisory Board (SAB).
  • Professor Honda is a Professor in the Department of Microbiology and Immunology at Keio University School of Medicine, Tokyo, Japan.
  • Dmitry Kuzmin, Managing Partner at 4BIO Capital, said: 4BIOs Scientific Advisory Board includes founders of the gene therapy field in both academic and hospital settings who lead groups in world centres of academic and clinical excellence.
  • Professor Hondas appointment builds on the recent appointment of Philippe Fauchet, OBE, as Venture Partner in Japan, and the strategic investment in 4BIO from Japanese Pharmaceutical company Kyowa Kirin.

4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board

Retrieved on: 
Lunedì, Luglio 13, 2020
American football in Japan, Keio University, Minato, Tokyo, Kirin

Brings extensive experience in gut microbiota, a core area of interest for 4BIO

Key Points: 
  • Brings extensive experience in gut microbiota, a core area of interest for 4BIO
    LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Kenya Honda to its Scientific Advisory Board (SAB).
  • Professor Honda is a Professor in the Department of Microbiology and Immunology at Keio University School of Medicine, Tokyo, Japan.
  • Dmitry Kuzmin, Managing Partner at 4BIO Capital, said: 4BIOs Scientific Advisory Board includes founders of the gene therapy field in both academic and hospital settings who lead groups in world centres of academic and clinical excellence.
  • Professor Hondas appointment builds on the recent appointment of Philippe Fauchet, OBE, as Venture Partner in Japan, and the strategic investment in 4BIO from Japanese Pharmaceutical company Kyowa Kirin.

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)

Retrieved on: 
Giovedì, Luglio 9, 2020
Life sciences, Articles, Biotechnology, Biosimilar, Drugs, Mylan, Fujifilm, Biopharmaceutical, Kirin, Food and Drug Administration

"The FDA approval of Hulio marks a significant milestone for both Fujifilm Kyowa Kirin Biologics and Mylan, increasing access to affordable treatment forU.S.

Key Points: 
  • "The FDA approval of Hulio marks a significant milestone for both Fujifilm Kyowa Kirin Biologics and Mylan, increasing access to affordable treatment forU.S.
  • Mylan and Fujifilm Kyowa Kirin Biologics entered into a partnership in 2018 for the commercialization of Hulio in Europe and Mylan has commercialized the product in severalcountries across the region.
  • In 2019, Mylan and Fujifilm Kyowa Kirin Biologics expanded the partnership globally.
  • Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President: Kenji Sukeno; hereinafter "Fujifilm") and Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, hereinafter "Kyowa Kirin") on March 27, 2012 as a company for developing, manufacturing, and marketing biosimilars.

Kyowa Kirin Names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America

Retrieved on: 
Lunedì, Giugno 29, 2020
Bastiani, Richard Posner, Kirin, Posner, Jurists, Philosophy, Legal professions

Most recently, Ms. Bastiani-Posner led the finance and IT functions as Senior Vice President, Finance Administration at the New York Genome Center, Inc.

Key Points: 
  • Most recently, Ms. Bastiani-Posner led the finance and IT functions as Senior Vice President, Finance Administration at the New York Genome Center, Inc.
  • "The North America region of Kyowa Kirin has the potential to grow substantially as we invest in our pipeline and our commercial portfolio," says Ms. Bastiani-Posner.
  • Ms. Bastiani-Posner succeeds Takeshi Masuda, who supported the finance team as an executive leader over the last several years with Kyowa Kirin.
  • "We are very pleased to have Ana Bastiani-Posner join our North America executive leadership team as Chief Financial Officer.

4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin

Retrieved on: 
Lunedì, Giugno 8, 2020
Kirin, Finance, Economy, Venture capital, Financial economics, Kirin Holdings

LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a leading Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, has made a strategic investment in 4BIOs Ventures II LP Fund.

Key Points: 
  • LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a leading Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, has made a strategic investment in 4BIOs Ventures II LP Fund.
  • Kyowa Kirin is one of the largest pharmaceutical and biotechnology companies in Japan with a global presence and is the first strategic pharmaceutical investor in 4BIO Ventures II.
  • The investment will provide Kyowa Kirin with access to the advanced therapies space across the UK, Europe and the US through 4BIOs investment team, while Kyowa Kirin will provide 4BIO with access to its scientific and R&D teams to better inform its ongoing investment in the space.
  • Kieran Mudryy, Partner at 4BIO Capital, said: We welcome Kyowa Kirins investment in the 4BIO Ventures II fund as testament to Japanese interests in advanced therapies, and our ability to identify the most exciting developments in the area.